HealthDay on MSN8h
Injectable Drug Resolves Dangerous Food Allergies In One-Third Of Kids
More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...
Healio3d
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...
The Motley Fool27d
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
First, a bit of background on the pain-drug environment ... That's why, following this recent FDA approval, Vertex stock makes a no-brainer biotech stock to buy and hold for the long term.
Pharmabiz13d
US FDA approves MED-EL USA’s SONNET 3 audio processor for MED-EL cochlear implants
US FDA approves MED-EL USA’s SONNET 3 audio processor for MED-EL cochlear implants: Durham, North Carolina Tuesday, February 18, 2025, 15:00 Hrs [IST] MED-EL USA, a leader in im ...
New Atlas2d
Gene therapy surgery restores some vision to legally blind children
Scientists in the UK have successfully used gene therapy to restore some vision to legally blind children with an inherited retinal condition. All 11 children in the clinical trial saw improvements ...
Apimeds Pharmaceuticals US Prices IPO at $4.00-$5.00 Per Share (APUS)
Apimeds Pharmaceuticals US (APUS) plans to raise $20 million in an initial public offering (IPO) on the week of March 10th, IPO Scoop reports. The company will issue 4,500,000 shares at $4.00-$5.00 ...
Harvard Medical School7h
Blavatnik Therapeutics Challenge Awards Fuel Translational Research
Three research teams have been selected as recipients of the 2024 Blavatnik Therapeutics Challenge Awards, an annual awards ...
Apimeds Pharmaceuticals US (APUS) Plans to Raise $20 Million in March 10th IPO
Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of March 10th, IPO Scoop reports. The company will issue 4,500,000 shares at a price of $4.
Yahoo Finance17d
MED-EL USA Announces FDA Approval of SONNET 3 Audio Processor with Built-In Direct Streaming, Compact Design and Enhanced Features
DURHAM, N.C., February 14, 2025--(BUSINESS WIRE)--MED-EL USA announced today that the U.S. Food and Drug Administration approved the new SONNET 3 audio ... This includes reducing distracting ...
Morningstar17d
MED-EL USA Announces FDA Approval of SONNET 3 Audio Processor with Built-In Direct Streaming, Compact Design and Enhanced Features
MED-EL USA announced today that the U.S. Food and Drug Administration approved the new SONNET 3 ... This includes reducing distracting background noises and leveraging dual microphones to allow ...
GlobalData on MSN13d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
Business Wire13d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
The safety and efficacy of this use has not been established by the U.S. FDA. There is currently no cure for HIV or AIDS. About Lenacapavir Lenacapavir is approved in multiple countries for the ...